Imaging cellularity in benign and malignant peripheral nerve sheath tumors: Utility of the "target sign" by diffusion weighted imaging

被引:38
|
作者
Ahlawat, Shivani [1 ]
Fayad, Laura M. [1 ,2 ,3 ]
机构
[1] Johns Hopkins Med Inst, Russell H Morgan Dept Radiol & Radiol Sci, 600 North Wolfe St, Baltimore, MD 21287 USA
[2] Johns Hopkins Med Inst, Dept Oncol, 600 North Wolfe St, Baltimore, MD 21287 USA
[3] Johns Hopkins Med Inst, Dept Orthopaed Surg, 600 North Wolfe St, Baltimore, MD 21287 USA
关键词
Target sign; Peripheral nerve sheath tumor; Diffusion weighted MRI; ADC mapping; Soft tissue mass; Neurofibromatosis; SOFT-TISSUE TUMORS; PROSTATE-CANCER; MR; DIFFERENTIATION; NEUROFIBROMAS; FEATURES; LESIONS; MASSES;
D O I
10.1016/j.ejrad.2018.03.018
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To determine the utility of "target sign" on diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping for peripheral nerve sheath tumor (PNST) characterization. Materials and methods: This IRB-approved, HIPAA-compliant study retrospectively reviewed the MR imaging (comprised of T2- FS, DWI (b-values 50, 400, 800 s/mm(2)and ADC mapping), and static contrast-enhanced (CE) T1-W imaging) of 42 patients (mean age: 40 years (range 8-68 years), 48% (20/42) females) with 15 malignant PNSTs (MPNSTs) and 33 benign PNSTs (BPNSTs). MPNSTs were histologically confirmed while BPNSTs were histologically-proven or with stable clinical and imaging appearance for at least 12 months. Two radiologists assessed imaging characteristics (size, signal intensity, heterogeneity, perilesional edema or enhancement) and the presence or absence of "target sign," on each sequence. A "target sign" was defined as a biphasic pattern of peripheral hyperintensity and homogeneous central hypointensity. Descriptive statistics are reported. Cohen's. statistic or interclass correlation coefficient (ICC) were used to evaluate interobserver agreement between two observers. Univariate and multiple logistic regression analysis were performed to identify MRI features with predictive values. Results: MPNSTs were larger than BPNSTs (6.3 +/- 2.5 cm vs 3.5 +/- -2.1 cm, p = 0.0002), had perilesional edema (87%(13/15) vs 18%(6/33), p < 0.0001), heterogeneous enhancement (71%(10/14) vs 13%(4/31), p = 0.0001) and perilesional enhancement (79%(11/14) vs 18%(6/31), p = 0.0001), respectively. The "target sign" was present in: 24%(8/33) BPNSTs vs 0/15 MPNST on T2-FS (p = 0.26); 39%(13/33) BPNSTs vs 20%(3/15) MPNST on DWI using b-value = 50 s/mm(2) (p = 0.5); 55%(18/33) BPNSTs vs 6%(1/15) MPNST on DWI using b-value = 400 s/mm(2) (p = 0.002); 48%(16/33) BPNSTs vs 6%(1/15) MPNST on DWI using b-value = 800 s/mm(2) (p = 0.005) and 64%(21/33) benign vs 0/15 MPNST on ADC mapping(p < 0.0001). By CET1 imaging, 32%(10/31) BPNSTs and 7%(1/14) MPNST had a target sign(p = 0.07). The odds of an MPNST in cases with minimum ADC <= 1.0 x 10(-3) mm(2)/s are 150 times higher than in cases with ADC > 1.0 x 10(-3). Conclusion: In this explorative study, a " target sign" suggests a benign PNST and is more often visible on DWI using high b-values and ADC maps compared with anatomic sequences.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 50 条
  • [31] Epithelial salivary gland tumors: Utility of radiomics analysis based on diffusion-weighted imaging for differentiation of benign from malignant tumors
    Shao, Shuo
    Mao, Ning
    Liu, Wenjuan
    Cui, Jingjing
    Xue, Xiaoli
    Cheng, Jingfeng
    Zheng, Ning
    Wang, Bin
    JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY, 2020, 28 (04) : 799 - 808
  • [32] Malignant Peripheral Nerve Sheath Tumors
    Gupta, Gaurav
    Mammis, Antonios
    Maniker, Allen
    NEUROSURGERY CLINICS OF NORTH AMERICA, 2008, 19 (04) : 533 - +
  • [33] Malignant Peripheral Nerve Sheath Tumors
    Durbin, Adam D.
    Ki, Dong Hyuk
    He, Shuning
    Look, A. Thomas
    CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS, 2016, 916 : 495 - 530
  • [34] Malignant peripheral nerve sheath tumors
    Perrin, RG
    Guha, A
    NEUROSURGERY CLINICS OF NORTH AMERICA, 2004, 15 (02) : 203 - +
  • [35] Malignant Peripheral Nerve Sheath Tumors
    Farid, Mohamad
    Demicco, Elizabeth G.
    Garcia, Roberto
    Ahn, Linda
    Merola, Pamela R.
    Cioffi, Angela
    Maki, Robert G.
    ONCOLOGIST, 2014, 19 (02): : 193 - 201
  • [36] Malignant Peripheral Nerve Sheath Tumors
    Khu, Kathleen Joy
    Midha, Rajiv
    WORLD NEUROSURGERY, 2016, 94 : 566 - 567
  • [37] PDGFR as a novel target for the treatment of malignant peripheral nerve sheath tumors
    Patwardhan, Parag
    Tap, William
    de Stanchina, Elisa
    Schwartz, Gary K.
    CANCER RESEARCH, 2012, 72
  • [38] Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors
    Ghadimi, Markus P.
    Young, Eric D.
    Belousov, Roman
    Zhang, Yiqun
    Lopez, Gonzalo
    Lusby, Kristelle
    Kivlin, Christine
    Demicco, Elizabeth G.
    Creighton, Chad J.
    Lazar, Alexander J.
    Pollock, Raphael E.
    Lev, Dina
    CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2545 - 2557
  • [39] Malignant peripheral nerve sheath tumor in spine: imaging manifestations
    Lang, Ning
    Liu, Xiao-Guang
    Yuan, Hui-Shu
    CLINICAL IMAGING, 2012, 36 (03) : 209 - 215
  • [40] Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging
    Well, Lennart
    Salamon, Johannes
    Kaul, Michael G.
    Farschtschi, Said
    Herrmann, Jochen
    Geier, Karin I.
    Hagel, Christian
    Bockhorn, Maximilian
    Bannas, Peter
    Adam, Gerhard
    Mautner, Victor F.
    Derlin, Thorsten
    NEURO-ONCOLOGY, 2019, 21 (04) : 508 - 516